

Wednesday, August 15 (Session 15B)

08:00 – **Registration** (University of Zurich, Entrance Hall)
08:30

Conference Day 2 Plenary Talk [KOH-B-10, floor B, video transmission to KOL-G-201 \(Aula\), floor G](#)

08:30 – Keynote 5 **Matthias Lutolf**, EPFL, Lausanne, CH
09:10 *Organoid development by design*
Intro: **Georg Duda**, Charité, Berlin, DE

Session 5B: Translational Session 1: Interfaces in the education and translation from science & technology to clinics & market: [KOL-G-201 \(Aula\), floor G](#)
Chair: **Alex Dommann**, Empa, CH

09:10 – Invited Translation- **Corina Schütt**, Hochschulmedizin Zurich, CH
09:25 Contribution 1 HMZ + Zurich Heart

09:25 – Invited Translation- **Uwe Freudenberg**, Max Bergmann Center of Biomaterials, Dresden, DE
09:40 Contribution 2 *ResCure: Hydrogels for healing chronic wounds*

09:40 – Invited Translation- **Volker Gatterdam**, Roche Pharma Research and Early Development, Roche Innovation Center Basel, CH
09:55 Contribution 3 *Focal Molography – The ongoing journey from an idea towards a product*

09:55 – Invited Translation- **Stefan Fischer**, Euresearch, CH
10:10 Contribution 4 *European Funding Opportunities for Research and Innovation Projects*

10:10 – **Coffee/Tea Break** / [Lichthof, floor D](#)
10:40

Session 5B (continued): Translational Session 1: Interfaces in the education and translation from science & technology to clinics & market: [KOL-G-201 \(Aula\), floor G](#) Chairs: **Daniel Ricklin**, University Basel, CH / **Aylvin Dias**, DSM Materials Science Center BV, NL

10:40 – Invited Translation- **Martin Kayser**, Wyss Zurich, CH
11:20 Contribution 4 *The Wyss Zurich model and challenges for translational medicine*
Maximilian Emmert, Wyss Zurich Project «LifeMatrix»

11:20 – Invited Translation- **Christian Mathis**, SuSoS AG, Dübendorf, CH
11:35 Contribution 5 *Molecular pocket-knife for next-generation diagnostics*

11:35 – Invited Translation- **Stephan Emmerth**, Baselaunch, **Jakob Busch-Petersen**, F. Hofmann-La Roche AG, Basel, CH
12:10 Contribution 6 *BaseLaunch and the role of incubators*
Simon Ittig, T3 Pharmaceutical AG, Basel, CH
A versatile bacterial cancer therapy: from idea to company

Wednesday, August 15 (Session 15B)

12:10 – **Lunch & Poster Session & Exhibition / Lichthof, floor D, Foyer West, floor D**
13:30

Session 6B: Translational Session 2: Sources of Innovation KOL-G-201 (Aula), floor G

Chairs: **David W. Grainger**, University of Utah, USA and **Michelle Grandin**, representing AMI-USC, LA, USA

13:30 – Invited Translation- **Daniela Marino**, Wyss Zurich Project «denovoSkin», Zurich, CH
13:45 Contribution 7 *Personalized tissue therapy: challenges and opportunities*

13:45 – Invited Translation- **Daniel Delfosse**, Mathys AG Bettlach, CH
14:00 Contribution 8 *Cooperation is the key for successful innovation*

14:00 – Invited Translation- **Curzio Rüegg**, Novigenix AG, University of Fribourg, CH
14:15 Contribution 9 *Cancer diagnostics: translating an idea into a product*

14:15 – Invited Translation- **Patrick Kugelmeier**, Kugelmeiers AG, Zollikerberg, CH
14:30 Contribution 10 *How laws of nature should guide the development of 3D cell culture for regenerative medicine*

14:30 - Panel Discussion Discussion Leader: **David W. Grainger**, University of Utah, USA
15:10 *Panelists: Speakers of above*

15:20 – **Coffee/TeaBreak / Lichthof, floor D**
15:50

Session 7B: Translational Session 3: Crossing regulatory and institutional barriers KOL-G-201 (Aula), floor G

Chairs: **Samuele Tosatti**, SuSoS AG, CH and **Martin Schuler**, AO Foundation, CH

15:50 – 16:05	Invited Translation- Contribution 11	Peter Studer , SwissMedtech, CH <i>The new EU-regulations and their impact on startup companies</i>
16:05 – 16:20	Invited Translation- Contribution 12	Martin Schuler , AO Foundation, Dübendorf, CH <i>Surviving the new MDR</i>
16:20 – 16:25	Invited Translation- Contribution 13	Beat Lechmann , Johnson & Johnson Medical Devices, Zuchwil, CH <i>MDR/IVDR implementation: what does it mean for my company?</i>
16:25 – 16:40	Invited Translation- Contribution 14	Lukas Langenegger , hemotune AG, Zurich, CH <i>The new MDR, what does it mean for Startups</i>

16:40 –
16:50 Q&A

16:50 –
17:00 *Short break (no servings)*

Conference Day 2 Plenary Talk KOH-B-10, floor B, video transmission to KOL-G-201 (Aula), floor G

17:00 –
17:40 Keynote 7 **David J. Mooney**, Harvard University, Cambridge, MA, USA
Manufacturing T cells in vitro and in vivo
Intro: **Sindy KY Tang**, Stanford University, Stanford, US

18:30 – ca. **Conference Dinner** (Restaurant “Die Waid”, Zurich)
23:00